Navigation Links
Valeant Pharmaceuticals Proposes to Acquire Cephalon, Inc. for $73 Per Share in Cash
Date:3/29/2011

a meaningful and productive dialogue regarding our proposal."

Mr. Pearson continued, "To be clear, we intend to be disciplined on price as we believe we have submitted a full and fair offer for Cephalon based on the information available to us.  If our offer does not have the requisite support of Cephalon's stockholders, we will focus our attention on other opportunities to invest our capital."  

Conference Call and Webcast Information

The Company will host a conference call and a live Internet webcast along with a slide presentation on March 30, 2011 at 8:30 a.m. ET (5:30 a.m. PT) to discuss an all-cash acquisition of Cephalon by Valeant. The dial-in number to participate on this call is (877) 295-5743, confirmation code 56043916. International callers should dial (973) 200-3961, confirmation code 56043916. A replay will be available approximately two hours following the conclusion of the conference call through April 6, 2011 and can be accessed by dialing (800) 642-1687, or (706) 645-9291, confirmation code 56043916. The live webcast of the conference call may be accessed through the investor relations section of the Company's corporate website at www.valeant.com.

About Valeant

Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) is a multinational specialty pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of neurology, dermatology and branded generics.  More information about Valeant can be found at www.valeant.com.

Forward-looking Statements

This press release may contain forward-looking statements, including, but not limited to, statements regarding Valeant's offer to acquire Cephalon, Valeant's intent to commence a consent solicitation process and its financing of the proposed transaction.  Forward-looking stat
'/>"/>

SOURCE Valeant Pharmaceuticals International, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related medicine technology :

1. Valeant to Acquire Polish Products
2. GSK and Valeant Announce New U.S. FDA PDUFA Goal Date for Ezogabine
3. Valeant and Biovail Announce Results of Special Meetings of Shareholders
4. Valeant Pharmaceuticals Announces Redemption and Defeasance of 7.625% Senior Notes Due 2020 and 8.375% Senior Notes Due 2016
5. Valeant Pharmaceuticals Announces That Alexza Pharmaceuticals Has Received a Complete Response Letter for AZ-004 (Staccato® Loxapine) Inhalation Aerosol NDA
6. Valeant Pharmaceuticals Reports 2010 Third Quarter Financial Results
7. Valeant Declares Special Dividend and Plans to Create a Special Dividend Reinvestment Plan
8. Valeant Announces Pricing of Senior Notes
9. Valeant Pharmaceuticals Announces Appointment of Robert A. Ingram and Resignation of William M. Wells as Chairman
10. Valeant Pharmaceuticals Appoints Philip W. Loberg as Interim CFO
11. Regulatory Update - GSK and Valeant Receive Positive Opinion in Europe From the CHMP for Trobalt (Retigabine)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... May 21, 2013  NxStage Medical, Inc. (Nasdaq: ... products, today announced that it has entered into new ... in-center products to DaVita, the kidney care division of ... ) For the use of products for ... , NxStage has executed a second amended and restated ...
(Date:5/21/2013)... New data released today at the ... that the NeuroStar TMS Therapy System ® ... in patients with Major Depressive Disorder (MDD) during ... through one year of treatment.  At the end ... symptomatic improvement while 41 percent reported complete remission. ...
(Date:5/21/2013)... Quebec , May 21, 2013 ... (NYSE: VRX ) (TSX: ... ten directors nominated at its 2013 ... detailed results of the vote for ... out below:  NameForWithheldRonald H. Farmer235,731,9341,964,748Robert A. ...
Breaking Medicine Technology:NxStage Announces New Agreements with DaVita 2New Data Show Long-Term Benefit of Transcranial Magnetic Stimulation in Difficult-to-Treat Patients with Depression using NeuroStar TMS Therapy System 2New Data Show Long-Term Benefit of Transcranial Magnetic Stimulation in Difficult-to-Treat Patients with Depression using NeuroStar TMS Therapy System 3New Data Show Long-Term Benefit of Transcranial Magnetic Stimulation in Difficult-to-Treat Patients with Depression using NeuroStar TMS Therapy System 4Valeant Pharmaceuticals Announces 2013 Annual Meeting Results 2
... Astellas Pharma US, Inc. ("Astellas") recently hired Mark ... oncology. Reporting directly to Patrick Shea, senior vice ... responsible for all U.S. commercial activities supporting marketed ... lead commercial planning for early stage development compounds. ...
... The Targetech Innovation Center, supported by a strategic ... developing pipeline of biomedical device opportunities poised to begin ... "This is an exciting development in the strategic ... effort, we will see more companies locating to Akron. ...
Cached Medicine Technology:Astellas Announces Vice President of Sales and Marketing for U.S. Oncology Franchise 2Akron Relationship with Israeli Incubator, Targetech, Shows Promise 2Akron Relationship with Israeli Incubator, Targetech, Shows Promise 3
(Date:5/21/2013)... 2013 Phoseon Technology will present their ... 20th Annual IMI European Ink Jet Conference (June ... Phoseon continues to invest in product development to enable ... UV LED curing in printing applications. Phoseon currently ... market offering both air cooled and water cooled solutions ...
(Date:5/21/2013)... (PRWEB) May 21, 2013 Modern ... the help of Texas Counseling’s Sexuality and Relationship ... and the development of healthier habits for their ... available for both couples and individuals at Texas ... their relationships and learn skills to develop long ...
(Date:5/21/2013)... Repository (DoDSR), University of Cincinnati (UC) researchers have identified ... which could help with earlier diagnosis and intervention in ... finding, the first of its kind and led by ... presentation by staff from Walter Reed National Military Medical ... 18-21 in Orlando, Fla. , The DoDSR is ...
(Date:5/21/2013)... May 21, 2013 The Las Vegas personal ... to announce that Crawford Gates, a senior at Coronado High ... college scholarship essay contest . As the winner of the ... essay contest started on Dec. 1, 2012 and ran through ... to submit a three-page minimum essay on “The Role of ...
(Date:5/21/2013)... A new study appearing in the ... stem cells harvested from fat (adipose) are more potent ... modulate the body’s immune system. , The finding ... as adipose tissue-derived stem cells (AT-SCs) are far more ... marrow and can be collected from waste material from ...
Breaking Medicine News(10 mins):Health News:Workshops Offered To Identify Underlying Challenges That Put Strain On Relationships 2Health News:Biomarkers discovered for inflammatory bowel disease 2Health News:Benson, Bertoldo, Baker & Carter is Pleased to Announce the Winner of its First Annual College Scholarship Essay Contest 2Health News:Stem Cells from Fat Outperform Those from Bone Marrow in Fighting Disease 2Health News:Stem Cells from Fat Outperform Those from Bone Marrow in Fighting Disease 3
... fears associated ... with common diabetes complication, ALEXANDRIA, Va., Oct. 4 ... ghosts and,goblins. But for some, there is something that is ... is a diabetes complication for both men and women.,According to ...
... N.J., Oct. 4 The National Confectioner,s,Association has ... go trick-or-treating,this year. With this in mind, Halloween ... brushing habits to their children. "Since candy ... eating on Halloween. Kids can enjoy chocolate and,lollipops ...
... benefit management ... organizations, ST. ... pharmacy benefit management, announced today it has,achieved URAC Pharmacy Benefit Management ... encourage PBM,industry best practices, promote quality improvement and protect and,empower consumers. ...
... 3 The following is a,statement by Michael Bender, ... credit, the US Food and Drug Administration and its ... a considerable,number of years to present a balanced and ... They recognized that there is,there is enough mercury in ...
... 3 EpiCept Corporation,(Nasdaq and OMX Nordic Exchange: ... will be presenting at the 2007 BIO InvestorForum ... at the Palace Hotel in San,Francisco, California. Mr. ... http://www.newscom.com/cgi-bin/prnh/20020513/NYM112LOGO ) The presentation will ...
... be allergic to,work? If you experience symptoms of allergies ... asthma. This disorder is defined as,reversible airflow obstruction caused ... harmful substances while "on the,job," according to the American ... that about 15%, or 1 in 7, of adult ...
Cached Medicine News:Health News:Diabetes in the Bedroom: Scarier than Halloween? 2Health News:Parents can Help Young Superheroes Battle Cavities on Halloween Night 2Health News:Prime Therapeutics Announces URAC Accreditation 2Health News:New Fish Advice Throws Baby Out With the Bath Water, Says Mercury Watchdog Group 2Health News:EpiCept Corporation to Present at the 2007 BIO InvestorForum 2Health News:EpiCept Corporation to Present at the 2007 BIO InvestorForum 3Health News:AAAAI: Asthma on the Job 2Health News:AAAAI: Asthma on the Job 3
MT-BT-5011-25 Prostate seeding needle (set of 25 unloaded needles).,MT-BT-5011-P Prostate seeding needle, pre-plugged and pre-sterilized, unloaded or for use with MEDTECs ASAP™ pre-load seedin...
... offers five classes of resectoscope electrodes ... loops, knife, roller bar & ball, ... only electrodes specifically integrated into the ... removal with minimal bleeding, increased visibility, ...
... and MRO™-2005 Rigid Percutaneous Nephroscopes combine ... throughput capacity with proven MRO performance. ... with small size sheaths. The MRO™-20 ... easy positioning during percutaneous procedures. The ...
... Resectoscope is based on the award winning ... the surgeon to perform TURis - resection ... element, HF cable and electrodes, Olympus OES ... in saline, supporting both, standard TUR and ...
Medicine Products: